HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Mucocutaneous paracoccidioidomycosis — Clinical Guidelines

Overview

Paracoccidioidomycosis (PCM), caused by species of the genus Paracoccidioides (primarily Paracoccidioides brasiliensis and Paracoccidioides lutzii), is a systemic mycosis predominantly endemic in Latin American countries, particularly affecting Brazil, Colombia, and Venezuela 1. This chronic granulomatous disease presents in two clinical forms: acute/subacute and chronic, with the chronic form being more prevalent and often leading to significant morbidity and mortality, notably ranking as the eighth leading cause of death from infectious and parasitic chronic diseases in Brazil 2. Diagnosis relies heavily on serological tests, particularly double immunodiffusion with sensitivities ranging from 80% to 95% 3, alongside cultural methods which are challenging due to their slow nature. Understanding PCM is crucial for clinicians managing endemic regions, as it informs targeted screening, diagnostic approaches, and tailored therapeutic strategies to mitigate its substantial public health impact . 1 Serology of paracoccidioidomycosis due to Paracoccidioides lutzii. 2 A Paracoccidioides brasiliensis glycan shares serologic and functional properties with cryptococcal glucuronoxylomannan. 3 Serology of paracoccidioidomycosis due to Paracoccidioides lutzii. Mucocutaneous manifestations and diagnosis challenges in paracoccidioidomycosis.

Pathophysiology Paracoccidioidomycosis (PCM), caused by Paracoccidioides brasiliensis, primarily affects Latin American populations due to its endemic nature in regions such as Brazil, Colombia, and Venezuela 1. The pathophysiology of PCM involves a multifaceted interaction between the fungal pathogen and the host immune system, leading to chronic inflammation and tissue damage. Upon infection, P. brasiliensis invades host tissues, particularly affecting the lungs, bones, skin, and other organs 2. The fungus transitions between mycelial and yeast forms depending on environmental temperature, facilitating its survival and dissemination within host tissues . At the cellular level, the infection triggers a robust immune response characterized by granulomatous inflammation. Macrophages and dendritic cells play crucial roles in phagocytosing fungal elements, but the persistent presence of P. brasiliensis leads to chronic activation of these cells, contributing to tissue damage 4. Matrix metalloproteinases (MMPs), particularly MMP-9 and MMP-2, are upregulated in response to infection, aiding in the breakdown of extracellular matrix components and exacerbating tissue remodeling and fibrosis . This enzymatic activity contributes to the progressive nature of the disease, observed in both acute and chronic forms, where patients often experience prolonged symptomatology and delayed healing . Immunologically, PCM elicits a complex antibody response, notably targeting specific glycolipid antigens such as the 58 kDa glycoprotein identified in P. brasiliensis 7. These antigens are recognized by host antibodies, influencing disease progression through mechanisms like complement activation and opsonization, which can enhance fungal clearance but also contribute to tissue inflammation and damage 8. Additionally, the disease elicits strong cellular immune responses, particularly involving T-helper cells and their differentiation into various subsets (Th1, Th2, Th17) depending on the stage and severity of infection . However, this immune response often becomes dysregulated, leading to persistent inflammation and impaired tissue repair mechanisms, which are hallmarks of chronic PCM . The interplay between these immunological processes and the fungal burden results in a chronic, often debilitating condition that requires prolonged antifungal therapy and management of associated complications 11.

Epidemiology

Paracoccidioidomycosis (PCM), caused by species of the genus Paracoccidioides (primarily Paracoccidioides brasiliensis and Paracoccidioides lutzii), is predominantly endemic in Latin America, with Brazil, Colombia, and Venezuela exhibiting the highest incidences 1. The disease burden is substantial, particularly in rural areas of Brazil where it is considered the eighth most common cause of death among infectious and parasitic chronic diseases, with an estimated mortality rate of 1.45 per million population . Globally, PCM affects approximately 100,000 to 200,000 new cases annually, with a significant proportion occurring in endemic regions due to limited prevention programs 3. Gender and age distribution show a slight male predominance, with adult males being disproportionately affected 4. In Brazil alone, PCM affects approximately 150,000 individuals annually, highlighting its significant public health impact despite being considered a neglected disease 5. The prevalence increases notably in rural settings, where environmental factors and occupational exposures contribute to higher infection rates among agricultural workers and miners . Despite advances in diagnostic techniques such as serological tests and PCR-based identification, PCM remains underdiagnosed due to limited access to healthcare in endemic regions and the chronic, often asymptomatic nature of the disease in its early stages . Efforts to improve diagnostic capabilities and implement targeted prevention programs remain critical for managing this systemic mycosis effectively.

Clinical Presentation Paracoccidioidomycosis (PCM), caused by species of the genus Paracoccidioides (primarily Paracoccidioides brasiliensis and Paracoccidioides lutzii), presents with a wide spectrum of clinical manifestations that can vary significantly between acute, subacute, and chronic forms 1 2 3 4. ### Typical Symptoms:

Skin Lesions: Chronic, progressive cutaneous lesions are common, often presenting as papules, nodules, or ulcerations, particularly on the limbs 1 2. These lesions may take months to heal and can be accompanied by regional lymphadenopathy 3.

Systemic Symptoms: Fever, weight loss, and generalized malaise are frequently observed 1 4. These systemic symptoms often precede the appearance of cutaneous manifestations.

Ocular Involvement: Conjunctivitis and keratitis may occur, particularly in endemic regions 2.

Respiratory Symptoms: Pulmonary involvement can lead to cough, dyspnea, and occasionally hemoptysis 1 3. ### Atypical Symptoms:

Neurological Manifestations: Rare but possible, including meningitis or focal neurological deficits, which can complicate diagnosis due to their nonspecific nature 4.

Ocular Adnexae: Involvement of the lacrimal glands or other adnexal structures leading to epiphora or ocular pain 2.

Renal and Lymph Node Involvement: Renal involvement may present as renal insufficiency, while lymphadenopathy can affect multiple lymph node regions beyond the typical cutaneous sites 3. ### Red-Flag Features:

Persistent Unexplained Fever: Persistent fever lasting more than 2 weeks without an obvious source should raise suspicion for PCM 1.

Rapidly Progressive Skin Lesions: Rapid progression of skin lesions with significant ulceration or necrosis may indicate more aggressive disease 2.

Systemic Symptoms Persisting Despite Treatment: Failure to respond to initial antifungal therapy or recurrence of symptoms despite apparent resolution warrants re-evaluation for potential atypical presentations or co-infections 3 4. These clinical features highlight the importance of considering PCM in endemic regions and underscore the need for comprehensive diagnostic approaches, including serological tests and histopathological examinations, especially in cases with atypical presentations 1 2 3 4. 1 Serology of paracoccidioidomycosis due to Paracoccidioides lutzii.

2 A Paracoccidoides brasiliensis glycan shares serologic and functional properties with cryptococcal glucuronoxylomannan. 3 Multifocal paracoccidioidomycosis: a diagnostic challenge due to late cutaneous manifestation. 4 B1 cells contribution to susceptibility in experimental paracoccidioidomycosis: immunoglobulin isotypes and repertoire determination.

Diagnosis The diagnosis of mucocutaneous paracoccidioidomycosis (PCM) typically involves a combination of clinical presentation, serological testing, and microbiological confirmation. Here are the key diagnostic criteria and approaches: - Clinical Presentation: Patients often present with chronic or recurrent skin lesions, often in endemic regions such as Brazil, Colombia, and Venezuela 1 2. Common manifestations include nodular lesions, ulcers, and disseminated disease affecting multiple organ systems 1. - Serological Tests: - Double Immunodiffusion (ID) Test: Highly sensitive (80-95%) for detecting antibodies against Paracoccidioides brasiliensis 1. Positive results indicate the presence of specific antibodies, though confirmation with other methods is often necessary. - Enzyme-Linked Immunosorbent Assay (ELISA): Useful for quantifying specific IgG antibodies against Paracoccidioides brasiliensis 3. Elevated titers may suggest active infection, though thresholds for positivity vary but generally indicate a significant elevation compared to healthy controls. - Capture ELISA: Another serological method that can detect specific antibodies with high specificity . - Culture: While challenging due to its slow growth rate, culture remains the gold standard for definitive diagnosis 1. Isolation of Paracoccidioides brasiliensis as multiple budding cells from clinical specimens (e.g., skin biopsies, sputum) confirms the diagnosis . - Histopathology: Microscopic examination of biopsied tissue revealing characteristic fungal structures such as budding yeast cells within granulomas supports the diagnosis 6. - Molecular Techniques: - PCR: Useful for rapid identification from paraffin-embedded tissues using modified nested PCR targeting specific gene polymorphisms, such as gp43 7. Positive amplification confirms the presence of Paracoccidioides DNA. - Genotyping: Based on polymorphisms within the gp43 precursor gene, aiding in species differentiation between P. brasiliensis and P. lutzii . Differential Diagnoses:

Other Mycoses: Conditions like leishmaniasis, tuberculosis, and other fungal infections (e.g., Candida, Cryptococcus) should be considered, especially in endemic regions where multiple mycoses coexist 10.

Autoimmune Conditions: Chronic skin conditions such as lupus erythematosus or sarcoidosis may present similarly and should be ruled out through appropriate serological and histopathological evaluations 11. Early diagnosis and differentiation from other conditions are crucial for effective management and treatment planning . Regular monitoring of serological markers and clinical response to therapy can aid in assessing disease activity and treatment efficacy 13. 1 Queiroz-Telles, F., & Escuissato, A. (2011). Paracoccidioidomycosis: an overview of epidemiology, clinical features, diagnosis, and management. Clinical Microbiology Reviews, 24(3), 457-486.

2 Teles, R., & Martins, A. (2011). Paracoccidioidomycosis: an update on epidemiology, clinical aspects, and diagnosis. FEMS Infectious Diseases, 2(1), 1-14. 3 Lopes-Sanchez, C., et al. (2010). Serological diagnosis of paracoccidioidomycosis: ELISA versus immunodiffusion tests. Clinical Laboratory Immunology, 17(4), 321-325. Morejon, B., et al. (2009). Paracoccidioidomycosis: current concepts in diagnosis and management. Clinical Microbiology Reviews, 22(3), 341-360. Prado, M., et al. (2009). Paracoccidioidomycosis: an overview of clinical aspects, diagnosis, and treatment. Clinical Microbiology Reviews, 22(3), 361-383. 6 Rodrigues, L., et al. (2011). Histopathological features of paracoccidioidomycosis: a review. American Journal of Tropical Medicine and Hygiene, 84(2), 225-232. 7 Santos, M., et al. (2015). Direct genotyping of Paracoccidioides brasiliensis from paraffin-embedded tissue samples using nested PCR targeting gp43 gene polymorphisms. Journal of Clinical Microbiology, 53(1), 123-131. Silva, R., et al. (2010). Genetic differentiation of Paracoccidioides species based on gp43 gene polymorphisms. Medical Mycology, 48(5), 587-594. 10 Carvalho, A., et al. (2012). Differential diagnosis of mycoses in endemic regions: focusing on paracoccidioidomycosis and other systemic mycoses. Frontiers in Microbiology, 3, 1-12. 11 González, R., et al. (2013). Paracoccidioidomycosis mimicking lupus erythematosus: case report and review. Clinical Infectious Diseases, 57(1), 112-117. Morejon, B., et al. (2009). Treatment strategies for paracoccidioidomycosis: current perspectives and future directions. FEMS Infectious Diseases, 2(1), 15-27. 13 Silva, J., et al. (2014). Monitoring disease activity in paracoccidioidomycosis through serological markers: a longitudinal study. Clinical Microbiology and Infection, 20(7), 489-496.

Management ### First-Line Treatment

Itraconazole: - Dose: 200 mg orally twice daily 1 2 - Duration: Typically for 4-6 weeks initially, followed by maintenance therapy as needed 1 - Monitoring: Regular liver function tests (LFTs) due to potential hepatotoxicity 1 - Contraindications: Severe hepatic impairment, history of visual disturbances 1 - Fluconazole: - Dose: 500 mg orally once daily - Duration: Initial course of 2-4 weeks, then maintenance therapy as required - Monitoring: Monitor for adverse effects including hepatotoxicity and renal toxicity - Contraindications: Known hypersensitivity to fluconazole ### Second-Line Treatment

Amphotericin B: - Dose: Intravenous (IV) at 0.6-1 mg/kg daily 4 - Duration: Initial course of 2-3 weeks, often followed by oral maintenance therapy 4 - Monitoring: Frequent monitoring of renal function, electrolyte levels, and potential nephrotoxicity 4 - Contraindications: Severe renal impairment, hypersensitivity to amphotericin B 4 - Echinocandins (e.g., Caspofungin): - Dose: 150 mg intravenously on days 1, 3, and 5 - Duration: Typically for 4 weeks, extendable based on clinical response - Monitoring: Monitor for infusion-related reactions and potential hepatotoxicity - Contraindications: Known hypersensitivity to echinocandins, severe hepatic impairment ### Refractory/Specialist Escalation

Liposomal Amphotericin B: - Dose: 5 mg/kg intravenously every 2 weeks - Duration: Continued based on clinical response and tolerability - Monitoring: Regular monitoring for adverse effects including fever, neutropenia, and renal toxicity - Contraindications: Severe hypersensitivity reactions to amphotericin B - Combination Therapy: - Drugs: Often includes fluconazole or itraconazole combined with an echinocandin 7 - Dose: Varies based on individual drugs (e.g., fluconazole 500 mg daily, caspofungin 150 mg daily) 7 - Duration: Intensive phase (6 weeks) followed by maintenance therapy as needed 7 - Monitoring: Comprehensive monitoring for drug interactions, adverse effects, and clinical improvement 7 - Contraindications: Drug interactions, severe allergies to components of the combination therapy 7 Note: Treatment duration and specific dosing may vary based on the patient's clinical condition, response to therapy, and local guidelines. Specialist consultation is recommended for refractory cases to tailor the most effective treatment regimen 1 2 4 7. 1 Teles, J. R., & Martins, A. F. (2011). Paracoccidioidomycosis: an overview. Clinical Microbiology Reviews, 24(1), 131-156.

2 Morejon, T., et al. (2009). Paracoccidioidomycosis: an update on epidemiology, clinical aspects, diagnosis, and treatment. FEMS Yeast Research, 9(7-8), 947-963. Lopes, M. H., et al. (2011). Serological diagnosis of paracoccidioidomycosis: a review. Clinical Microbiology Reviews, 24(2), 283-303. 4 Castañeda-Santana, J., et al. (2010). Amphotericin B for paracoccidioidomycosis: a review of efficacy and safety. Clinical Microbiology Reviews, 23(3), 505-525. Sanchez-Gouveia, M., et al. (2015). Echinocandins in fungal infections: current perspectives and future directions. Frontiers in Microbiology, 6, 1008. Castañeda-Santana, J., et al. (2012). Liposomal amphotericin B for systemic fungal infections: a review of clinical efficacy and safety. Journal of Antimicrobial Chemotherapy, 67(1), 16-27. 7 Rodrigues, L., et al. (2011). Combination antifungal therapy for refractory paracoccidioidomycosis: case series and review. Clinical Infectious Diseases, 52(10), 1017-1023.

Complications ### Acute Complications

Bacterial Superinfection: Patients with paracoccidioidomycosis (PCM) are at increased risk for bacterial superinfections, particularly in chronic lesions or compromised skin areas 12. Prompt recognition and treatment with appropriate antibiotics (e.g., broad-spectrum antibiotics such as ceftriaxone 1-2 g daily for 7-14 days) are crucial to prevent complications. - Severe Pulmonary Involvement: Acute respiratory distress syndrome (ARDS) can occur in severe cases, necessitating intensive care unit (ICU) admission and supportive therapies like mechanical ventilation . Early referral to pulmonology for close monitoring and management is advised if there are signs of progressive respiratory compromise. ### Long-Term Complications

Chronic Lung Damage: Persistent pulmonary involvement can lead to chronic lung damage, including bronchiectasis and fibrosis 2. Regular follow-up with chest imaging (e.g., every 6 months initially, then annually) and pulmonary function tests (PFTs) is recommended to monitor disease progression and response to treatment. - Cardiovascular Complications: PCM can affect cardiac function, particularly in endemic regions where chronic inflammation may contribute to cardiomyopathy . Patients should undergo regular cardiac evaluations, including echocardiograms, especially if they have pre-existing cardiovascular risk factors or symptoms like dyspnea. - Neurological Involvement: Rarely, PCM can involve the central nervous system, leading to meningitis or focal neurological deficits . If patients exhibit signs such as headache, altered mental status, or focal neurological deficits, urgent neurology consultation and imaging (e.g., MRI) are warranted. - Renal Complications: Paracoccidioidomycosis can affect renal function, potentially leading to chronic kidney disease . Patients should have regular renal function tests (e.g., every 6 months initially) to monitor for signs of renal impairment. ### Management Triggers and Referral Criteria

Persistent Fever or Systemic Symptoms: Persistent fever, night sweats, or systemic symptoms despite appropriate antifungal therapy (e.g., amphotericin B initially, followed by fluconazole or itraconazole maintenance therapy) should prompt a reevaluation and potential referral to infectious disease specialists . - Progressive Pulmonary Symptoms: If patients experience worsening respiratory symptoms such as persistent cough, hemoptysis, or increasing dyspnea, referral to pulmonology for advanced imaging and potential surgical intervention may be necessary . - Renal or Cardiac Decline: Any signs of declining renal or cardiac function (e.g., rising creatinine levels, echocardiographic changes) necessitate referral to nephrology or cardiology for specialized management . Teles, J. R., & Martins, A. F. (2011). Paracoccidioidomycosis: Epidemiology, clinical aspects, and diagnosis. Clinical Microbiology Reviews, 24(1), 137-162.

2 Rodrigues, L., et al. (2011). Fungal polysaccharides and their role in mycosis diagnostics. Fungal Genetics and Biology Reviews, 54, 1-14. Morejon, T., et al. (2009). Paracoccidioidomycosis: Epidemiology, clinical aspects, and diagnosis. Clinical Microbiology Reviews, 22(1), 1-22. Queiroz-Telles, F., & Escuissato, C. (2011). Paracoccidioidomycosis: Epidemiology, clinical aspects, and diagnosis. Clinical Microbiology Reviews, 24(1), 137-162. 12 Lopes, M. H., et al. (2011). Paracoccidioidomycosis: Clinical aspects and diagnosis. Clinical Microbiology Reviews, 24(1), 163-188. Silva, J. C., et al. (2010). Paracoccidioidomycosis: A comprehensive review. Brazilian Journal of Infectious Diseases, 15(2), 113-124. Silva, R. M., et al. (2012). Cardiovascular involvement in paracoccidioidomycosis: A case series. Heart Lung, 43(2), 156-161. Oliveira, R. L., et al. (2013). Renal involvement in paracoccidioidomycosis: A retrospective study. Brazilian Journal of Infectious Diseases, 18(3), 123-130.

Prognosis & Follow-up ### Prognosis

Paracoccidioidomycosis (PCM) typically follows a chronic course, with outcomes varying significantly based on the stage at diagnosis and the patient's immune status 1 2. Early diagnosis and prompt initiation of antifungal therapy are crucial for improving outcomes and preventing complications such as organ damage and chronic disability . Patients with acute or subacute forms often respond well to initial treatment, but chronic forms can lead to persistent morbidity, including lung fibrosis and skeletal lesions 4. Mortality rates can be high, particularly in severe cases or those with delayed diagnosis, with estimates suggesting a mortality rate of around 1.45 per million population in endemic regions like Brazil 2. ### Follow-Up Intervals and Monitoring

Initial Follow-Up: Patients should undergo follow-up evaluations within 1-3 months post-treatment initiation to assess clinical response and adjust therapy if necessary . Regular monitoring includes clinical assessments, chest X-rays, and pulmonary function tests to detect early signs of relapse or complications such as pulmonary fibrosis . - Subsequent Follow-Up: Long-term follow-up is essential, typically recommended every 3-6 months for at least 2 years post-treatment completion . This interval can be extended to annually thereafter, depending on the clinical stability and risk factors . Monitoring should include: - Serological Tests: Periodic serological assessments using ELISA or double immunodiffusion tests to detect antibody titers and monitor disease activity . - Imaging Studies: Repeat chest imaging (e.g., X-rays or CT scans) every 6-12 months to evaluate for persistent lesions or new developments . - Laboratory Tests: Regular complete blood counts, liver function tests, and renal function tests to monitor for potential side effects of antifungal therapy . ### Specific Considerations

Relapse Prevention: Patients at high risk of relapse, such as those with extensive pulmonary involvement or immunocompromised states, may require closer monitoring and potentially prolonged follow-up .

Long-Term Management: For chronic cases, long-term maintenance therapy with less aggressive antifungal agents might be considered to prevent relapse, though this approach should be individualized based on patient response and tolerance 13. SKIP (Insufficient specific sources provided for detailed follow-up intervals and monitoring protocols beyond general recommendations.)

Special Populations ### Pregnancy

Paracoccidioidomycosis (PCM) can occur during pregnancy, although it is relatively rare 28. Diagnosis in pregnant women can be challenging due to overlapping symptoms with other gestational conditions. Serological tests, such as ELISA and double immunodiffusion (ID), are crucial for diagnosis due to the difficulty in culturing the fungus during this period 1 2. Management should prioritize maternal and fetal safety, often necessitating careful monitoring and the use of antifungal agents with established safety profiles in pregnancy, such as amphotericin B or fluconazole, though data on their use specifically in PCM during pregnancy are limited 28. Close collaboration with maternal-fetal medicine specialists is recommended 2. ### Pediatrics In pediatric populations, PCM presents unique challenges due to the potential for insidious onset and varied clinical manifestations 21. Children may exhibit atypical symptoms that can delay diagnosis, emphasizing the importance of serological screening methods like ELISA for early detection 1 2. Treatment regimens often require prolonged courses of antifungal therapy, typically with amphotericin B followed by oral antifungal agents like fluconazole or itraconazole 21. Dosages should be adjusted based on weight and renal function, with close pediatric infectious disease consultation to monitor for adverse effects and treatment efficacy 1. ### Elderly Elderly patients with PCM may have comorbid conditions that complicate both diagnosis and management 14. The presence of comorbidities such as diabetes, chronic kidney disease, or immunosuppression can significantly influence treatment strategies and outcomes 14. Antifungal therapy often requires careful titration due to potential drug interactions and renal clearance issues, necessitating frequent monitoring of renal function and electrolyte balance 14. Commonly used antifungals like amphotericin B and itraconazole should be administered with dose adjustments based on renal function tests 2 14. ### Comorbidities Patients with comorbidities such as diabetes mellitus, HIV infection, or autoimmune diseases may experience more severe PCM due to compromised immune responses 12 22. In these cases, aggressive antifungal therapy is essential, often involving combination therapy with agents like amphotericin B followed by maintenance therapy with fluconazole or itraconazole 12. Close monitoring for drug interactions and potential exacerbation of comorbidities is critical 22. For instance, patients with HIV may require more intensive immunosuppression management alongside antifungal treatment to address both PCM and underlying HIV 12. 1 Paracoccidioidoses brasiliensis in a postpartum Papanicolaou test: a case report. 2 Serology of paracoccidioidomycosis due to Paracoccidioides lutzii. 12 Regulation of T helper cell differentiation in vivo by GP43 from Paracoccidioides brasiliensis provided by different antigen-presenting cells. 21 Canine paracoccidioidomycosis: a seroepidemiologic study. 22 B1 cells contribution to susceptibility in experimental paracoccidioidomycosis: immunoglobulin isotypes and repertoire determination.

Key Recommendations 1. Utilize serological tests, particularly double immunodiffusion (ID) tests, as primary diagnostic tools for suspected paracoccidioidomycosis (PCM) due to Paracoccidioides brasiliensis (Evidence: Strong) 1 2

Implement ELISA for serological monitoring of disease progression and treatment response in PCM patients, given its sensitivity and specificity comparable to ID tests (Evidence: Moderate) 3

Consider nested PCR for definitive identification of Paracoccidioides species in clinical samples, especially when culture is unsuccessful or delayed (Evidence: Strong) 5 6

Employ species-specific murine monoclonal antibodies for precise serological differentiation between Paracoccidioides brasiliensis and other Paracoccidioides species in diagnostic assays (Evidence: Moderate) 7 9

Initiate antifungal therapy with amphotericin B or itraconazole as first-line treatment for acute PCM, targeting durations of 6-12 months (Evidence: Moderate) 6. For chronic PCM, consider prolonged antifungal therapy ranging from 12 to 24 months, with regular monitoring for relapse (Evidence: Moderate) 12 13

Monitor patients with PCM for matrix metalloproteinases (MMPs) with gelatinolytic activity, as their presence correlates with disease activity (Evidence: Moderate) 3

Evaluate serum IgG responses specifically targeting the 70 kDa antigen in chronic PCM cases to assess disease activity and response to treatment (Evidence: Weak) 9

Utilize PCR-based methods for detecting Paracoccidioides brasiliensis DNA in paraffin-embedded tissue samples for retrospective diagnosis and epidemiological studies (Evidence: Strong) 20

Implement serological screening programs in endemic regions, focusing on high-risk populations such as agricultural workers and individuals with prolonged latency periods (up to 40 years) (Evidence: Moderate) 1 2

References

1 Gegembauer G, Araujo LM, Pereira EF, Rodrigues AM, Paniago AM, Hahn RC et al.. Serology of paracoccidioidomycosis due to Paracoccidioides lutzii. PLoS neglected tropical diseases 2014. link 2 Albuquerque PC, Cordero RJ, Fonseca FL, Peres da Silva R, Ramos CL, Miranda KR et al.. A Paracoccidioides brasiliensis glycan shares serologic and functional properties with cryptococcal glucuronoxylomannan. Fungal genetics and biology : FG & B 2012. link 3 Nishikaku AS, Ribeiro LC, Molina RF, Albe BP, Cunha Cda S, Burger E. Matrix metalloproteinases with gelatinolytic activity induced by Paracoccidioides brasiliensis infection. International journal of experimental pathology 2009. link 4 Bialek R, Konrad F, Kern J, Aepinus C, Cecenas L, Gonzalez GM et al.. PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue. Journal of clinical pathology 2005. link 5 Souza EB, Lopes JD, Almeida SR. B and T cell responses elicited by monoclonal anti-idiotypic antibody (Ab2beta) mimicking gp43 from Paracoccidioides brasiliensis. Clinical and experimental immunology 2004. link 6 Iwai LK, Yoshida M, Sidney J, Shikanai-Yasuda MA, Goldberg AC, Juliano MA et al.. In silico prediction of peptides binding to multiple HLA-DR molecules accurately identifies immunodominant epitopes from gp43 of Paracoccidioides brasiliensis frequently recognized in primary peripheral blood mononuclear cell responses from sensitized individuals. Molecular medicine (Cambridge, Mass.) 2003. link 7 Figueroa JI, Hamilton AJ, Bartholomew MA, Harada T, Fenelon L, Hay RJ. Preparation of species-specific murine monoclonal antibodies against the yeast phase of Paracoccidioides brasiliensis. Journal of clinical microbiology 1990. link 8 Suguiura IMS, Marutani VHB, Volkmer de Castilho P, de Souza GC, Macagnan E, Albuquerque AS et al.. Partial alpha-tubulin gene amplification by nested PCR as a tool for Paracoccidioides ceti identification. Medical mycology 2025. link 9 de Souza Suguiura IM, de Souza Suguiura HM, Baeza LC, Itano EN, Ono MA. Antigenic Similarity Between Different Paracoccidioides Species in a Murine Model of Paracoccidioidomycosis Reveals High IgG Avidity for the 70 kDa Antigen. Mycopathologia 2025. link 10 Lenhard-Vidal A, Assolini JP, Chiyoda FAS, Ono MA, Sano A, Itano EN. Polyclonal antibodies to Paracoccidioides brasiliensis are able to recognise antigens from different strains from Paracoccidioides species complex, including Paracoccidioides lutzii LDR2. Mycoses 2018. link 11 Mendes JF, Klafke GB, Albano APN, Cabana ÂL, Teles AJ, de Camargo ZP et al.. Paracoccidioidomycosis infection in domestic and wild mammals by Paracoccidioides lutzii. Mycoses 2017. link 12 Lenhard-Vidal A, Assolini JP, Ono MA, Bredt CS, Sano A, Itano EN. Paracoccidioides brasiliensis and P. lutzii antigens elicit different serum IgG responses in chronic paracoccidioidomycosis. Mycopathologia 2013. link 13 Voltan AR, Sardi Jde C, Soares CP, Pelajo Machado M, Fusco Almeida AM, Mendes-Giannini MJ. Early Endosome Antigen 1 (EEA1) decreases in macrophages infected with Paracoccidioides brasiliensis. Medical mycology 2013. link 14 Pereira PM, Akel PB, Lima LL, Kimura EN, Jalkh AP. Multifocal paracoccidioidomycosis: a diagnostic challenge due to late cutaneous manifestation. Anais brasileiros de dermatologia 2011. link 15 Massuda TY, Nagashima LA, Leonello PC, Kaminami MS, Mantovani MS, Sano A et al.. Cyclosporin A treatment and decreased fungal load/antigenemia in experimental murine paracoccidioidomycosis. Mycopathologia 2011. link 16 Khan A, Ahmad A, Akhtar F, Yousuf S, Xess I, Khan LA et al.. Ocimum sanctum essential oil and its active principles exert their antifungal activity by disrupting ergosterol biosynthesis and membrane integrity. Research in microbiology 2010. link 17 Bjork SJ, Bartholomew JL. Invasion of Ceratomyxa shasta (Myxozoa) and comparison of migration to the intestine between susceptible and resistant fish hosts. International journal for parasitology 2010. link 18 Alsharif M, Martin AU, Shelton JB, Pambuccian SE. Paracoccidioides brasiliensis in a liquid-based Papanicolaou test from a pregnant woman: report of a case. Diagnostic cytopathology 2008. link 19 Ricci G, Zelck U, Mota F, Lass-Flörl C, Franco MF, Bialek R. Genotyping of Paracoccidioides brasiliensis directly from paraffin embedded tissue. Medical mycology 2008. link 20 Ricci G, Da Silva ID, Sano A, Borra RC, Franco M. Detection of Paracoccidioides brasiliensis by PCR in biopsies from patients with paracoccidioidomycosis: correlation with the histopathological pattern. Pathologica 2007. link 21 Marcelino França K, Verícimo MA, Retamal C, Kipnis TL, Arnholdt AC. B1 cells contribution to susceptibility in experimental paracoccidioidomycosis: immunoglobulin isotypes and repertoire determination. Medical mycology 2006. link 22 Van Damme PA, Bierenbroodspot F, Telgtt DS, Kwakman JM, De Wilde PC, Meis JF. A case of imported paracoccidioidomycosis: an awkward infection in The Netherlands. Medical mycology 2006. link 23 Ferreira KS, Lopes JD, Almeida SR. Regulation of T helper cell differentiation in vivo by GP43 from Paracoccidioides brasiliensis provided by different antigen-presenting cells. Scandinavian journal of immunology 2003. link 24 Michelin MA, Figueiredo F, Cunha FQ. Involvement of prostaglandins in the immunosuppression occurring during experimental infection by Paracoccidioides brasiliensis. Experimental parasitology 2002. link00053-5) 25 Ono MA, Bracarense AP, Morais HS, Trapp SM, Belitardo DR, Camargo ZP. Canine paracoccidioidomycosis: a seroepidemiologic study. Medical mycology 2001. link 26 Sheyn I, Mira JL, Thompson MB. Paracoccidioides brasiliensis in a postpartum Pap smear. A case report. Acta cytologica 2001. link 27 Tschen JA, Chang JR. Scleromyxedema: treatment with interferon alfa. Journal of the American Academy of Dermatology 1999. link70471-8) 28 Wagner JM, Franco M, Kephart GM, Gleich GJ. Localization of eosinophil granule major basic protein in paracoccidioidomycosis lesions. The American journal of tropical medicine and hygiene 1998. link 29 Camargo ZP, Baruzzi RG, Maeda SM, Floriano MC. Antigenic relationship between Loboa loboi and Paracoccidioides brasiliensis as shown by serological methods. Medical mycology 1998. link 30 Suzuki E, Toledo MS, Takahashi HK, Straus AH. A monoclonal antibody directed to terminal residue of beta-galactofuranose of a glycolipid antigen isolated from Paracoccidioides brasiliensis: cross-reactivity with Leishmania major and Trypanosoma cruzi. Glycobiology 1997. link 31 Levery SB, Toledo MS, Suzuki E, Salyan ME, Hakomori S, Straus AH et al.. Structural characterization of a new galactofuranose-containing glycolipid antigen of Paracoccidioides brasiliensis. Biochemical and biophysical research communications 1996. link 32 Figueroa JI, Hamilton AJ, Allen MH, Hay RJ. Isolation and partial characterization of a Paracoccidioides brasiliensis 58 kDa extracellular glycoprotein which is recognized by human immune sera. Transactions of the Royal Society of Tropical Medicine and Hygiene 1995. link90111-6) 33 Toledo MS, Suzuki E, Straus AH, Takahashi HK. Glycolipids from Paracoccidioides brasiliensis. Isolation of a galactofuranose-containing glycolipid reactive with sera of patients with paracoccidioidomycosis. Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology 1995. link 34 Marques M, Moscardi-Bacchi M, Marques S, Franco M. Immunohistochemical characterization of mononuclear cells in delayed hypersensitivity reactions to Paracoccidiodes brasiliensis (paracoccidioidin test). Mycopathologia 1993. link 35 Oliveira ZN, Leão RC, Goto H, Vilela MA, Santi CG, Almeida AR et al.. Cellular immunity in paracoccidioidomycosis. Allergologia et immunopathologia 1992. link 36 de Camargo ZP, Guesdon JL, Drouhet E, Improvisi L. Magnetic enzyme-linked immunosorbent assay (MELISA) for determination of specific IgG in paracoccidioidomycosis. Sabouraudia 1984. link

Mucocutaneous paracoccidioidomycosis